Neuronetics to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call

Rhea-AI Summary

MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) plans to release its Q3 2022 financial results on November 8, 2022, prior to market open. A conference call will follow at 8:30 a.m. ET to discuss the results, with a live webcast available. Neuronetics focuses on improving mental health through its NeuroStar Advanced Therapy, a non-invasive treatment for mood disorders like major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). NeuroStar has delivered over 4.8 million treatments and is backed by extensive clinical data.

MALVERN, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release third quarter 2022 financial and operating results prior to market open on Tuesday, November 8^th, 2022. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/h3amkwib. To listen to the conference call on your telephone, participants may register for the call here. While it is not required, it is recommended you join 10 minutes prior to the event start.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 4.8 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com.

Investor Contact:
Mike Vallie or Mark Klausner
ICR Westwicke
443-213-0499
ir@neuronetics.com

Media Contact:
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com

FAQ

When will Neuronetics release its Q3 2022 financial results for STIM?

Neuronetics plans to release its Q3 2022 financial results on November 8, 2022.

What time is the Neuronetics conference call for Q3 2022 results?

The conference call is scheduled for 8:30 a.m. Eastern Time on November 8, 2022.

How can I listen to Neuronetics' Q3 conference call?

The conference call can be listened to via a live webcast available on the Neuronetics website.

What is NeuroStar Advanced Therapy by Neuronetics?

NeuroStar Advanced Therapy is a non-invasive treatment for major depressive disorder and OCD, delivering over 4.8 million treatments.

What clinical data supports NeuroStar treatment?

NeuroStar is backed by the largest clinical data set for TMS systems, including the world's largest depression Outcomes Registry.